Amgen (AMGN) Share-based Compensation (2009 - 2026)
Amgen (AMGN) posted quarterly Share-based Compensation of $75.0 million for Q1 2026, down 11.76% year-over-year from $85.0 million in Q1 2025, and down 40.0% quarter-over-quarter from $125.0 million in Q4 2025.
Amgen (AMGN) Share-based Compensation (2009 - 2026) Analysis & Trends
Amgen's Share-based Compensation history runs 14 years deep, the most recent figure standing at $75.0 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 11.76% year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $484.0 million (down 5.47% YoY), while the FY2025 annual figure was $494.0 million, down 6.79% from the prior year.
- Share-based Compensation for Q1 2026 stood at $75.0 million, down from $125.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $161.0 million in Q4 2023, with the low at $47.0 million in Q1 2023.
- The 4-year median for Share-based Compensation is $125.0 million (2025), against an average of $117.7 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 119.15% in 2024, then retreated 17.48% in 2025.
- Amgen's Share-based Compensation stood at $161.0 million in 2023, then decreased by 16.77% to $134.0 million in 2024, then fell by 6.72% to $125.0 million in 2025, then sank by 40.0% to $75.0 million in 2026.
- Business Quant data shows AMGN's Share-based Compensation at $75.0 million in Q1 2026, $125.0 million in Q4 2025, and $127.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.00 Mn |
| Jun 30, 2026 | 165.00 Mn |
| Mar 31, 2026 | 75.00 Mn |
| Mar 31, 2026 | 75.00 Mn |
| Dec 31, 2025 | 125.00 Mn |
| Dec 31, 2025 | 125.00 Mn |
| Sep 30, 2025 | 127.00 Mn |
| Sep 30, 2025 | 127.00 Mn |
| Jun 30, 2025 | 157.00 Mn |
| Jun 30, 2025 | 157.00 Mn |
| Mar 31, 2025 | 85.00 Mn |
| Mar 31, 2025 | 85.00 Mn |
| Dec 31, 2024 | 134.00 Mn |
| Dec 31, 2024 | 134.00 Mn |
| Sep 30, 2024 | 136.00 Mn |
| Sep 30, 2024 | 136.00 Mn |
| Jun 30, 2024 | 157.00 Mn |
| Jun 30, 2024 | 157.00 Mn |
| Mar 31, 2024 | 103.00 Mn |
| Mar 31, 2024 | 103.00 Mn |